Because of the rise in hemoglobin A1c and hyperglycemia, the patient was prescribed dulaglutide 0.75 mg/mL weekly, which is a novel glucagon-like protein-1 (GLP-1) receptor agonist injection for treating type 2 diabetes (enhances insulin production in the pancreas and lowers glucose production in the liver). This evidence concerns the gene INS and type 2 diabetes mellitus.